Double-digit revenue growth
Three new contracts signed in September, including first wearables contract
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2017.
The Company is pleased to report revenue for the year of £3.7 million (2016: £3.1 million). The £0.6 million increase, or c.20% growth over the prior year, reflects traction in the Company’s commercially led organic growth strategy focused on the global biopharma market. As a result the Company expects to be ahead of expectations for EBITDA and operating losses for the current financial year.Click edit button to change this text.